A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient

Cellestia is pleased to share a case report of complete clinical response in a patient with relapsed and refractory T-ALL after treatment with Cellestia’s CSL-NICD inhibitor CB-103 thanks to the collaboration with the team of the Department of Hematology, University Hospital Basel. The study has been just published in a peer reviewed journal (eJHaem published by British Society for Haematology).

Please see here the link to the paper for your read.

No previous newsNo next news